Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2024-03-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
致同会计师事务所（特殊普通合伙）关于新天地药业股份有限公司2023年度募集资金存放与实际使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Assurance Report) regarding the "2023年度募集资金存放与实际使用情况" (2023 Annual Fundraising Funds Deposit and Actual Usage Situation) for 新天地药业股份有限公司. It is issued by a certified public accounting firm and includes detailed financial data about the company's fundraising, usage, and management of raised funds during the fiscal year 2023. The document references regulatory guidelines related to fundraising management and usage, and it provides tables with actual financial figures and explanations of fund usage. This is a specialized audit or assurance report focused on the company's fundraising funds, not a full annual report or earnings release. It is a standalone audit-type report verifying the use of raised capital, which fits the definition of an Audit Report / Information (AR). The document length is substantial (15,000 characters), and it contains substantive financial data and analysis, not merely an announcement or certification letter. Therefore, the appropriate classification is AR (Audit Report / Information).
2024-03-25 Chinese
第五届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board meeting of Xintiandi Pharmaceutical Co., Ltd. It discusses the approval of various reports and proposals related to the 2023 fiscal year, including the 2023 Annual Report, Supervisory Board Work Report, Financial Statements, Internal Control Self-Evaluation Report, Fund Usage Report, Profit Distribution Plan, remuneration for Supervisors, Supervisory Board election nominations, appointment of the auditing firm, and related financial and governance matters. The document repeatedly states that the detailed reports are disclosed separately on the CNINFO website and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself is a meeting resolution announcement, not the full annual report or financial statements. It is relatively short (3551 characters) and serves as an official announcement of meeting decisions rather than containing the full reports or detailed financial data. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for such announcements that do not contain the full report or detailed financial data but announce resolutions and approvals related to them.
2024-03-25 Chinese
华泰联合证券有限责任公司关于新天地药业股份有限公司2023年度募集资金存放和使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from Huatai United Securities Co., Ltd., acting as the sponsor institution, regarding the special inspection of the deposit and use of raised funds by Xintiandi Pharmaceutical Co., Ltd. for the year 2023. It includes specific financial figures about the amount raised, usage, balances, investment projects, and compliance with regulatory requirements. The content focuses on the management and use of funds raised through a public stock issuance, with detailed tables and explanations of fund allocation and investment progress. This matches the characteristics of an Audit Report / Information (AR) as it is a standalone report on the use and management of raised funds, including verification and compliance details, rather than a full annual report or an announcement. The document is substantive and detailed, not merely an announcement or certification, and does not fit other categories such as capital update or regulatory filing. Therefore, the appropriate classification is AR. FY 2023
2024-03-25 Chinese
关于监事会换届选举的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the election of the supervisory board members (监事会换届选举) of the company 新天地药业股份有限公司. It details the nomination and qualifications of candidates for the supervisory board, the legal basis for the election, and the process to be followed. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management discussion. The content is about changes in the supervisory board, which is part of the company's governance structure but specifically about board/management changes. Therefore, the document fits best under Board/Management Information (MANG). The document length is short (1777 characters), consistent with an announcement rather than a full report.
2024-03-25 Chinese
关于公司通过药品GMP符合性检查的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding passing a GMP (Good Manufacturing Practice) compliance inspection for a pharmaceutical product. It includes details about the inspection, regulatory body (Henan Provincial Drug Administration), and implications for production and sales. The document is short (767 characters) and serves as a regulatory compliance update rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed governance information. It is an official regulatory announcement about compliance status, fitting best under Regulatory Filings (RNS) as it does not match other specific categories like Annual Report, Earnings Release, or Management Reports.
2024-02-21 Chinese
关于收到政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from a company about receiving government subsidies. It includes details about the accounting treatment of the subsidy but does not contain financial statements or detailed financial analysis. The length is only 397 characters, indicating it is a brief notice rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is an announcement related to financing (government subsidy), but not a detailed capital or financing update. The best fit is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2024-02-01 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.